Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease

Annals of Pharmacotherapy

Volumn 49, Issue 9, 2015, Pages 986-994

  García Martín, Paloma ^a   Alarcón Payer, Carolina ^a   López Fernández, Elisa ^a   Moratalla, Lucía ^a   Romero, Antonio ^a   Sainz, Juan ^a,b   Ríos, Rafael ^a,b   Jurado, Manuel ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

cyclosporine; hematology; immunosuppressants; prophylaxis; transplants

Indexed keywords

CYCLOSPORIN; DEFIBROTIDE; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; RITUXIMAB; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; COMPARATIVE STUDY; COMPASSIONATE USE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; TERTIARY CARE CENTER; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME TO TREATMENT; TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; ADVERSE EFFECTS; CHRONIC DISEASE; GRAFT VS HOST DISEASE; MORTALITY; RECURRENT DISEASE; THROMBOTIC MICROANGIOPATHIES;

ACUTE DISEASE; ADULT; CALCINEURIN INHIBITORS; CHRONIC DISEASE; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SIROLIMUS; THROMBOTIC MICROANGIOPATHIES;

EID: 84940206690     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015593369     Document Type: Article

References (47)

1. E.HollerH.J.KolbE.HillerMicroangiopathy in patients on cyclosporin prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989;73:2018-2024.
2. T.RuutuJ.HermansD.NiederwieserThrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2002;118:1112-1119.
3. C.CutlerN.L.HenryC.MageeSirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:551-557.
4. C.CutlerB.LoganR.NakamuraTacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation. Blood. 2014;124:1372-1377.
5. V.T.HoC.CutlerS.CarterBlood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571-575.
6. T.RuutuG.BarosiR.J.BenjaminDiagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92:95-100.
7. J.H.AntinH.T.KimC.CutlerSirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003;102:1601-1605.
8. C.CutlerH.T.KimE.HochbergSirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:328-336.
9. E.P.AlyeaS.LiH.T.KimSirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:920-926.
10. R.RodriguezR.NakamuraJ.M.PalmerA phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115:1098-1105.
11. L.L.RosenbeckP.J.KielI.KalsekarProphylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:916-922.
12. R.NakamuraJ.M.PalmerM.R.O’DonnellReduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis. Leuk Res. 2012;36:1152-1156.
13. Z.Al-KadhimiZ.GulR.RodriguezAnti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1734-1744.
14. O.RingdénM.RembergerG.DahllöfSirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. Eur J Haematol. 2011;87:503-509.
15. J.PidalaJ.KimH.JimA randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012;97:1882-1889.
16. S.K.KhaledJ.PalmerT.StillerA phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. Bone Marrow Transplant. 2013;48:278-283.
17. J.A.Perez-SimónR.MartinoR.ParodyThe combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica. 2013;98:526-532.
18. A.I.BenitoT.FurlongP.J.MartinSirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2001;72:1924-1929.
19. D.R.CourielR.SalibaM.P.EscalónSirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130:409-417.
20. M.JuradoC.VallejoJ.A.Pérez-SimónSirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:701-706.
21. J.PidalaJ.KimC.Anasetti. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15:881-885.
22. D.GhezM.T.RubioN.MaillardRapamycin for refractory acute graft-versus-host disease. Transplantation. 2009;88:1081-1087.
23. D.HodaJ.PidalaN.Salgado-VilaSirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010;45:1347-1351.
24. Z.JedlickovaI.BurlakovaG.BugH.BaurmannR.SchwerdtfegerM.Schleuning. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors. Biol Blood Marrow Transplant. 2011;17:657-663.
25. J.PidalaM.TomblynT.NishihoriSirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica. 2011;96:1351-1356.
26. C.MasloM.N.PeraldiJ.C.DesenclosThrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997;24:350-355.
27. M.E.ChappellD.M.KeelingH.G.PrenticeP.Sweny. Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?Bone Marrow Transplant. 1988;3:339-347.
28. E.HollerH.J.KolbE.HillerMicroangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989;73:2018-2024.
29. J.RosenthalA.PawlowskaE.BolotinTransplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer. 2011;57:142-146.
30. S.ShayaniJ.PalmerT.StillerThrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013;19:298-304.
31. J.LabradorL.López-CorralO.López-GodinoRisk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplant. 2014;49:684-690.
32. B.L.LaskinJ.GoebelS.M.DaviesS.Jodele. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011;118:1452-1462.
33. A.CarmonaM.Díaz-RicartM.PalomoDistinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. Biol Blood Marrow Transplant. 2013;19:1439-1445.
34. G.G.CamiciJ.SteffelI.AmanovicRapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur Heart J. 2010;31:236-242.
35. C.CutlerH.T.KimS.AyanianPrediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010;16:1180-1185.
36. F.ShihabU.ChristiansL.SmithJ.R.WellenB.Kaplan. Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure–response relationships, and clinical outcomes. Transpl Immunol. 2014;31:22-32.
37. C.MarzoliniE.PausT.BuclinR.B.Kim. Polymorphisms in human MDR1 a (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
38. F.ThiebautT.TsuruoH.HamadaM.M.GottesmanI.PastanM.C.Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84:7735-7738.
39. Y.ZhangL.Z.Benet. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40:159-168.
40. K.MahalatiB.D.Kahan. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40:573-585.
41. L.Becquemont. Clinical relevance of pharmacogenetics. Drug Metab Rev. 2003;35:277-285.
42. R.ArceciK.StieglitzB.Bierer. Immunosuppressants FK506 and Rapamycin function as reversal agents of the multidrug resistance phenotype. Blood. 1992;80:1528-1536.
43. K.L.NapoliM.E.WangS.M.StepkowskiB.D.Kahan. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic. Ther Drug Monit. 1998;20:123-133.
44. D.BatesK.W.BurakC.S.CoffinT.YingE.M.Enns. Phenytoin-induced reduction in sirolimus levels. Can J Hosp Pharm. 2011;64:271-274.
45. D.J.FreemanA.LaupacisP.A.KeownC.R.StillerS.G.Carruthers. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol. 1984;18:887-893.
46. E.StavrouH.M.Lazarus. Thrombotic microangiopathy in haematopoietic cell transplantation: an update. Mediterr J Hematol Infect Dis. 2010;2:e2010033.
47. A.K.Khanna. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation. 2000;70:690-694.